Posted by Michael Wonder on 15 May 2024
Atogepant monohydrate for the prevention of migraine
15 May 2024 - NICE has published final evidence-based recommendations on atogepant monohydrate (Aquipta) for preventing migraine in adults.
Atogepant monohydrate is recommended as an option for the prevention of migraine in adults who have at least four migraine days per month, only if at least three preventive medicines have failed.
